Eli Lilly and Company (NYSE: LLY) hit the new year running when it announced the acquisition of Loxo Oncology, Inc. (NASDAQ: LOXO), a biopharmaceutical company that develops medicines for genomically defined cancers. Under the terms of the deal, Lilly will acquire all outstanding shares of Loxo for $235.00 per share, or $8 billion. The offer […]
ARMO BioSciences (NASDAQ: ARMO) is a late-stage immuno-oncology company that develops a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors. On a trailing 12-month basis, it generated a net loss of $42.4 million. Eli Lilly and Company (NYSE: LLY) overlooked the loss as […]
Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.
In the first quarter of 2017, pharmaceutical deals dropped even further, compared with the previous quarter, and the same quarter the year before.
The Pharmaceutical sector hasn’t wasted any time getting busy in the New Year. As of January 18, 2017, 10 pharma deals have been announced, with disclosed prices totaling $7.18 billion. Of course, the annual JP Morgan Healthcare Summit, held this year from January 9 to January 13, helped to boost the announcements. The largest deal so […]